{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:30:19Z","timestamp":1793053819888,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"MEXT KAKENHI","award":["JP23K08169"],"award-info":[{"award-number":["JP23K08169"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79252-y","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T19:31:02Z","timestamp":1735327862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Extensive methylation analysis of circulating tumor DNA in plasma of patients with gastric cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Shinnosuke","family":"Nagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Hagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Momose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyokazu","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"79252_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.31662\/jmaj.2018-0006","volume":"1","author":"T Hashimoto","year":"2018","unstructured":"Hashimoto, T., Kurokawa, Y., Mori, M. & Doki, Y. Update on the treatment of gastric cancer. JMA J 1, 40\u201349 (2018).","journal-title":"JMA J"},{"key":"79252_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S2468-1253(18)30090-6","volume":"3","author":"Y Kurokawa","year":"2018","unstructured":"Kurokawa, Y. et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): A phase 3, open-label, randomised controlled trial. Lancet Gastroenterol. Hepatol. 3, 460\u2013468 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"79252_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/bjs\/znac373","volume":"110","author":"Y Kurokawa","year":"2022","unstructured":"Kurokawa, Y. et al. Five-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001). Br. J. Surg. 110, 50\u201356 (2022).","journal-title":"Br. J. Surg."},{"key":"79252_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ags3.12711","volume":"7","author":"Y Yanagimoto","year":"2023","unstructured":"Yanagimoto, Y., Kurokawa, Y. & Doki, Y. Essential updates 2021\/2022: Perioperative and surgical treatments for gastric and esophagogastric junction cancer. Ann. Gastroenterol. Surg. 7, 698\u2013708 (2023).","journal-title":"Ann. Gastroenterol. Surg."},{"key":"79252_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ags3.12632","volume":"7","author":"Y Kurokawa","year":"2023","unstructured":"Kurokawa, Y. et al. Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage III gastric or esophagogastric junction adenocarcinoma. Ann. Gastroenterol. Surg. 7, 247\u2013254 (2023).","journal-title":"Ann. Gastroenterol. Surg."},{"key":"79252_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s10120-020-01112-1","volume":"24","author":"Y Kurokawa","year":"2021","unstructured":"Kurokawa, Y. et al. Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3). Gastric Cancer 24, 428\u2013434 (2021).","journal-title":"Gastric Cancer"},{"key":"79252_CR7","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","volume":"27","author":"EC Smyth","year":"2016","unstructured":"Smyth, E. C. et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27, v38\u2013v49 (2016).","journal-title":"Ann. Oncol."},{"key":"79252_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10120-013-0259-5","volume":"17","author":"H Shimada","year":"2014","unstructured":"Shimada, H., Noie, T., Ohashi, M., Oba, K. & Takahashi, Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 17, 26\u201333 (2014).","journal-title":"Gastric Cancer"},{"key":"79252_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00595-016-1408-3","volume":"47","author":"N Wada","year":"2017","unstructured":"Wada, N. et al. The characteristics of the serum carcinoembryonic antigen and carbohydrate antigen 19\u20139 levels in gastric cancer cases. Surg. Today 47, 227\u2013232 (2017).","journal-title":"Surg. Today"},{"key":"79252_CR10","doi-asserted-by":"crossref","unstructured":"Zhao, L., Li, M., Zhang, S. & Liu, Y. Plasma-methylated SEPT9 for the noninvasive diagnosis of gastric cancer. J. Clin. Med. Res. 11 (2022).","DOI":"10.3390\/jcm11216399"},{"key":"79252_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/annonc\/mdz001","volume":"30","author":"D Dong","year":"2019","unstructured":"Dong, D. et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann. Oncol. 30, 431\u2013438 (2019).","journal-title":"Ann. Oncol."},{"key":"79252_CR12","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker, J. D. et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J. Clin. Oncol. 36, 1631\u20131641 (2018).","journal-title":"J. Clin. Oncol."},{"key":"79252_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531\u2013548 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"79252_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12943-021-01309-7","volume":"20","author":"J Hou","year":"2021","unstructured":"Hou, J., Li, X. & Xie, K.-P. Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication. Mol. Cancer 20, 34 (2021).","journal-title":"Mol. Cancer"},{"key":"79252_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12943-021-01371-1","volume":"20","author":"M Nagasaka","year":"2021","unstructured":"Nagasaka, M. et al. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol. Cancer 20, 82 (2021).","journal-title":"Mol. Cancer"},{"key":"79252_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12943-018-0757-5","volume":"17","author":"SY Lim","year":"2018","unstructured":"Lim, S. Y., Lee, J. H., Diefenbach, R. J., Kefford, R. F. & Rizos, H. Liquid biomarkers in melanoma: detection and discovery. Mol. Cancer 17, 8 (2018).","journal-title":"Mol. Cancer"},{"key":"79252_CR17","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","volume":"368","author":"S-J Dawson","year":"2013","unstructured":"Dawson, S.-J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199\u20131209 (2013).","journal-title":"N. Engl. J. Med."},{"key":"79252_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/bjc.2014.609","volume":"112","author":"T Hamakawa","year":"2015","unstructured":"Hamakawa, T. et al. Monitoring gastric cancer progression with circulating tumour DNA. Br. J. Cancer 112, 352\u2013356 (2015).","journal-title":"Br. J. Cancer"},{"key":"79252_CR19","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1245\/s10434-018-6502-x","volume":"25","author":"EJAH van Beek","year":"2018","unstructured":"van Beek, E. J. A. H. et al. Rates of TP53 mutation are significantly elevated in African American patients with gastric cancer. Ann. Surg. Oncol. 25, 2027\u20132033 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"79252_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.823905","volume":"13","author":"Y Zeng","year":"2022","unstructured":"Zeng, Y. et al. DNA methylation: An important biomarker and therapeutic target for gastric cancer. Front. Genet. 13, 823905 (2022).","journal-title":"Front. Genet."},{"key":"79252_CR21","doi-asserted-by":"publisher","first-page":"7187","DOI":"10.1158\/0008-5472.CAN-11-1349","volume":"71","author":"K Matsusaka","year":"2011","unstructured":"Matsusaka, K. et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 71, 7187\u20137197 (2011).","journal-title":"Cancer Res."},{"key":"79252_CR22","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-17-3364","volume":"24","author":"BW Anderson","year":"2018","unstructured":"Anderson, B. W. et al. Detection of gastric cancer with novel methylated DNA markers: Discovery, tissue validation, and pilot testing in plasma. Clin. Cancer Res. 24, 5724\u20135734 (2018).","journal-title":"Clin. Cancer Res."},{"key":"79252_CR23","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1007\/s10620-020-06710-8","volume":"66","author":"H Yan","year":"2021","unstructured":"Yan, H. et al. Value of plasma methylated SFRP2 in prognosis of gastric cancer. Dig. Dis. Sci. 66, 3854\u20133861 (2021).","journal-title":"Dig. Dis. Sci."},{"key":"79252_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23936","volume":"35","author":"X-Y Hu","year":"2021","unstructured":"Hu, X.-Y. et al. Circulating methylated THBS1 DNAs as a novel marker for predicting peritoneal dissemination in gastric cancer. J. Clin. Lab. Anal. 35, e23936 (2021).","journal-title":"J. Clin. Lab. Anal."},{"key":"79252_CR25","doi-asserted-by":"publisher","first-page":"153303382097327","DOI":"10.1177\/1533033820973279","volume":"20","author":"EI Karamitrousis","year":"2021","unstructured":"Karamitrousis, E. I. et al. Prognostic role of RASSF1A, SOX17 and Wif-1 promoter methylation status in cell-free DNA of advanced gastric cancer patients. Technol. Cancer Res. Treat. 20, 1533033820973279 (2021).","journal-title":"Technol. Cancer Res. Treat."},{"key":"79252_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000442948","volume":"90","author":"N Wada","year":"2016","unstructured":"Wada, N. et al. Detecting secondary C-KIT mutations in the peripheral blood of patients with imatinib-resistant gastrointestinal stromal tumor. Oncology 90, 112\u2013117 (2016).","journal-title":"Oncology"},{"key":"79252_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000504808","volume":"98","author":"T Hagi","year":"2020","unstructured":"Hagi, T. et al. Molecular barcode sequencing for highly sensitive detection of circulating tumor DNA in patients with esophageal squamous cell carcinoma. Oncology 98, 222\u2013229 (2020).","journal-title":"Oncology"},{"key":"79252_CR28","doi-asserted-by":"crossref","unstructured":"Jensen, L. H. et al. NPY gene methylation as a universal, longitudinal plasma marker for evaluating the clinical benefit from last-line treatment with regorafenib in metastatic colorectal cancer. Cancers 11 (2019).","DOI":"10.3390\/cancers11111649"},{"key":"79252_CR29","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1016\/j.clcc.2018.02.006","volume":"17","author":"N Boeckx","year":"2018","unstructured":"Boeckx, N. et al. Mutation and methylation analysis of circulating tumor DNA can be used for follow-up of metastatic colorectal cancer patients. Clin. Colorectal Cancer 17, e369\u2013e379 (2018).","journal-title":"Clin. Colorectal Cancer"},{"key":"79252_CR30","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1158\/1078-0432.CCR-22-1500","volume":"29","author":"K Janssens","year":"2023","unstructured":"Janssens, K. et al. NPY methylated ctDNA is a promising biomarker for treatment response monitoring in metastatic colorectal cancer. Clin. Cancer Res. 29, 1741\u20131750 (2023).","journal-title":"Clin. Cancer Res."},{"key":"79252_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad923","author":"Z Zhu","year":"2023","unstructured":"Zhu, Z. et al. MethMarkerDB: A comprehensive cancer DNA methylation biomarker database. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkad923 (2023).","journal-title":"Nucleic Acids Res."},{"key":"79252_CR32","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s13104-021-05809-z","volume":"14","author":"C Yu","year":"2021","unstructured":"Yu, C. et al. Repeatability of methylation measures using a QIAseq targeted methyl panel and comparison with the Illumina HumanMethylation450 assay. BMC Res. Notes 14, 394 (2021).","journal-title":"BMC Res. Notes"},{"key":"79252_CR33","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s12032-013-0830-2","volume":"31","author":"H Zhang","year":"2014","unstructured":"Zhang, H. et al. Detection of aberrant hypermethylated spastic paraplegia-20 as a potential biomarker and prognostic factor in gastric cancer. Med. Oncol. 31, 830 (2014).","journal-title":"Med. Oncol."},{"key":"79252_CR34","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1038\/onc.2011.109","volume":"30","author":"GE Lind","year":"2011","unstructured":"Lind, G. E. et al. SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis. Oncogene 30, 3967\u20133978 (2011).","journal-title":"Oncogene"},{"key":"79252_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218338","volume":"14","author":"K-L Wei","year":"2019","unstructured":"Wei, K.-L. et al. Methylomics analysis identifies a putative STAT3 target, SPG20, as a noninvasive epigenetic biomarker for early detection of gastric cancer. PLoS ONE 14, e0218338 (2019).","journal-title":"PLoS ONE"},{"key":"79252_CR36","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3892\/ol.2021.12911","volume":"22","author":"R Kerslake","year":"2021","unstructured":"Kerslake, R. et al. A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer. Oncol. Lett. 22, 650 (2021).","journal-title":"Oncol. Lett."},{"key":"79252_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/657570","volume":"2015","author":"W-H Li","year":"2015","unstructured":"Li, W.-H. et al. Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer. Dis. Markers 2015, 657570 (2015).","journal-title":"Dis. Markers"},{"key":"79252_CR38","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jmoldx.2013.03.004","volume":"15","author":"T Oh","year":"2013","unstructured":"Oh, T. et al. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J. Mol. Diagn. 15, 498\u2013507 (2013).","journal-title":"J. Mol. Diagn."},{"key":"79252_CR39","doi-asserted-by":"publisher","first-page":"658","DOI":"10.21037\/tcr.2017.08.04","volume":"6","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Expression of Syndecan-2 in gastric adenocarcinoma and its effect on tumorigenesis in vitro. Transl. Cancer Res. 6, 658\u2013666 (2017).","journal-title":"Transl. Cancer Res."},{"key":"79252_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.860701","volume":"12","author":"L Ma","year":"2022","unstructured":"Ma, L. et al. A novel stool methylation test for the non-invasive screening of gastric and colorectal cancer. Front. Oncol. 12, 860701 (2022).","journal-title":"Front. Oncol."},{"key":"79252_CR41","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2147\/IJGM.S395951","volume":"16","author":"J Guo","year":"2023","unstructured":"Guo, J., Li, J., Chang, J., Wang, L. & Xi, Y. Value of methylation status of RPRM, SDC2, and TCF4 genes in plasma for gastric adenocarcinoma screening. Int. J. Gen. Med. 16, 673\u2013681 (2023).","journal-title":"Int. J. Gen. Med."},{"key":"79252_CR42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cancergencyto.2009.11.004","volume":"197","author":"H Takada","year":"2010","unstructured":"Takada, H. et al. Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer. Cancer Genet. Cytogenet. 197, 16\u201324 (2010).","journal-title":"Cancer Genet. Cytogenet."},{"key":"79252_CR43","doi-asserted-by":"publisher","first-page":"84054","DOI":"10.18632\/oncotarget.21097","volume":"8","author":"H Hu","year":"2017","unstructured":"Hu, H. et al. The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer. Oncotarget 8, 84054\u201384065 (2017).","journal-title":"Oncotarget"},{"key":"79252_CR44","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.ejca.2008.12.027","volume":"45","author":"CD Jee","year":"2009","unstructured":"Jee, C. D., Kim, M. A., Jung, E. J., Kim, J. & Kim, W. H. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur. J. Cancer 45, 1282\u20131293 (2009).","journal-title":"Eur. J. Cancer"},{"key":"79252_CR45","first-page":"3835","volume":"31","author":"K Hibi","year":"2011","unstructured":"Hibi, K. et al. Detection of TFPI2 methylation in the serum of gastric cancer patients. Anticancer Res. 31, 3835\u20133838 (2011).","journal-title":"Anticancer Res."},{"key":"79252_CR46","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/clinchem\/hvab204","volume":"68","author":"J Ren","year":"2022","unstructured":"Ren, J. et al. Genome-scale methylation analysis of circulating cell-free DNA in gastric cancer patients. Clin. Chem. 68, 354\u2013364 (2022).","journal-title":"Clin. Chem."},{"key":"79252_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/cm.21488","volume":"76","author":"K Nakos","year":"2019","unstructured":"Nakos, K., Rosenberg, M. & Spiliotis, E. T. Regulation of microtubule plus end dynamics by septin 9. Cytoskeleton 76, 83\u201391 (2019).","journal-title":"Cytoskeleton"},{"key":"79252_CR48","first-page":"3433406","volume":"2022","author":"W Li","year":"2022","unstructured":"Li, W. et al. SNHG3 affects gastric cancer development by regulating SEPT9 methylation. J. Oncol. 2022, 3433406 (2022).","journal-title":"J. Oncol."},{"key":"79252_CR49","doi-asserted-by":"publisher","first-page":"6289063","DOI":"10.1155\/2020\/6289063","volume":"2020","author":"B Li","year":"2020","unstructured":"Li, B. et al. SEPT9 gene methylation as a noninvasive marker for hepatocellular carcinoma. Dis. Markers 2020, 6289063 (2020).","journal-title":"Dis. Markers"},{"key":"79252_CR50","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/clinchem\/hvad084","volume":"69","author":"D Dietrich","year":"2023","unstructured":"Dietrich, D. et al. Circulating cell-free SEPT9 DNA methylation in blood is a biomarker for minimal residual disease detection in head and neck squamous cell carcinoma patients. Clin. Chem. 69, 1050\u20131061 (2023).","journal-title":"Clin. Chem."},{"key":"79252_CR51","doi-asserted-by":"crossref","unstructured":"Jin, S. et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc. Natl. Acad. Sci. USA 118 (2021).","DOI":"10.1073\/pnas.2017421118"},{"key":"79252_CR52","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1593\/tlo.13118","volume":"6","author":"HS Lee","year":"2013","unstructured":"Lee, H. S. et al. Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon. Transl. Oncol. 6, 290\u2013296 (2013).","journal-title":"Transl. Oncol."},{"key":"79252_CR53","doi-asserted-by":"publisher","first-page":"7012","DOI":"10.21037\/tcr-20-1330","volume":"9","author":"C-Q Cao","year":"2020","unstructured":"Cao, C.-Q., Chang, L. & Wu, Q. Circulating methylated Septin 9 and ring finger protein 180 for noninvasive diagnosis of early gastric cancer. Transl. Cancer Res. 9, 7012\u20137021 (2020).","journal-title":"Transl. Cancer Res."},{"key":"79252_CR54","doi-asserted-by":"publisher","first-page":"175883592091847","DOI":"10.1177\/1758835920918472","volume":"12","author":"CB Thomsen","year":"2020","unstructured":"Thomsen, C. B. et al. Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer. Ther. Adv. Med. Oncol. 12, 1758835920918472 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"79252_CR55","doi-asserted-by":"publisher","first-page":"1205791","DOI":"10.3389\/fonc.2023.1205791","volume":"13","author":"E Lukacova","year":"2023","unstructured":"Lukacova, E. et al. Hypermethylated GRIA4, a potential biomarker for an early non-invasive detection of metastasis of clinically known colorectal cancer. Front. Oncol. 13, 1205791 (2023).","journal-title":"Front. Oncol."},{"key":"79252_CR56","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/path.6047","volume":"259","author":"W Wang","year":"2023","unstructured":"Wang, W. et al. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA. J. Pathol. 259, 376\u2013387 (2023).","journal-title":"J. Pathol."},{"key":"79252_CR57","first-page":"2098","volume":"6","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. Methylation of serum SST gene is an independent prognostic marker in colorectal cancer. Am. J. Cancer Res. 6, 2098\u20132108 (2016).","journal-title":"Am. J. Cancer Res."},{"key":"79252_CR58","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/cam4.5008","volume":"12","author":"SK Pedersen","year":"2023","unstructured":"Pedersen, S. K. et al. Detection of methylated BCAT1 and IKZF1 after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence. Cancer Med. 12, 1319\u20131329 (2023).","journal-title":"Cancer Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79252-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79252-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79252-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T20:07:34Z","timestamp":1735330054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79252-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79252"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79252-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30739"}}